Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
Portfolio Pulse from Vandana Singh
Novo Nordisk has acquired 2seventy Bio's Hemophilia A program and related gene editing technology. 2seventy Bio will now focus exclusively on its CAR T cell therapy, Abecma, in collaboration with Bristol Myers Squibb. The deal could bring up to $40 million to 2seventy Bio.
June 27, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
2seventy Bio will now focus on the commercialization and development of Abecma, its CAR T cell therapy for multiple myeloma, in collaboration with Bristol Myers Squibb.
The exclusive focus on Abecma could lead to accelerated development and commercialization, benefiting Bristol Myers Squibb as a collaborator.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Novo Nordisk has acquired 2seventy Bio's Hemophilia A program and related gene editing technology. This acquisition expands Novo Nordisk's portfolio in gene editing and Hemophilia A treatment.
The acquisition enhances Novo Nordisk's capabilities in gene editing and Hemophilia A treatment, potentially leading to new product developments and market expansion.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
2seventy Bio has sold its Hemophilia A program to Novo Nordisk and will now focus on its CAR T cell therapy, Abecma, in collaboration with Bristol Myers Squibb. The deal could bring up to $40 million to 2seventy Bio.
The divestiture allows 2seventy Bio to concentrate on its core CAR T cell therapy, potentially increasing operational efficiency and focus. The potential $40 million from the deal is a positive financial boost.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100